LT3199172T - Dozavimo režimas, skirtas išsėtinei sklerozei - Google Patents

Dozavimo režimas, skirtas išsėtinei sklerozei

Info

Publication number: LT3199172T
Authority: LT; Lithuania
Prior art keywords: multiple sclerosis; dosing regimen; regimen; dosing; sclerosis
Prior art date: 2009-08-20

Application number

LTEP17157735.6T

Other languages

English (en)

Inventor

Ety Klinger

Original Assignee

Yeda Research And Development Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-20

Filing date

2010-08-19

Publication date

2018-10-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43605835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3199172(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-08-19 Application filed by Yeda Research And Development Co., Ltd. filed Critical Yeda Research And Development Co., Ltd.

2018-10-25 Publication of LT3199172T publication Critical patent/LT3199172T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Neurology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Magnetic Resonance Imaging Apparatus (AREA)

LTEP17157735.6T 2009-08-20 2010-08-19 Dozavimo režimas, skirtas išsėtinei sklerozei LT3199172T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27468709P	2009-08-20	2009-08-20
US33761210P	2010-02-11	2010-02-11

Publications (1)

Publication Number	Publication Date
LT3199172T true LT3199172T (lt)	2018-10-25

Family

ID=43605835

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LTEP15171065.4T LT2949335T (lt)	2009-08-20	2010-08-19	Žemo dažnio glatiramero acetato terapija
LTEP13166080.5T LT2630962T (lt)	2009-08-20	2010-08-19	Mažo dažnio glatiramero acetato terapija
LTEP17157735.6T LT3199172T (lt)	2009-08-20	2010-08-19	Dozavimo režimas, skirtas išsėtinei sklerozei

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
LTEP15171065.4T LT2949335T (lt)	2009-08-20	2010-08-19	Žemo dažnio glatiramero acetato terapija
LTEP13166080.5T LT2630962T (lt)	2009-08-20	2010-08-19	Mažo dažnio glatiramero acetato terapija

Country Status (34)

Country	Link
US (15)	US8399413B2 (lt)
EP (5)	EP2405749B1 (lt)
JP (3)	JP6038653B2 (lt)
KR (4)	KR20140061559A (lt)
CN (3)	CN102625657A (lt)
AR (2)	AR077896A1 (lt)
AT (1)	AT15421U1 (lt)
AU (1)	AU2010284666B2 (lt)
BR (1)	BR112012003730A2 (lt)
CA (2)	CA2760802C (lt)
CY (2)	CY1114537T1 (lt)
CZ (2)	CZ30474U1 (lt)
DE (1)	DE202010018377U1 (lt)
DK (5)	DK2405749T3 (lt)
EA (3)	EA032283B1 (lt)
ES (4)	ES2689711T3 (lt)
HK (2)	HK1258008A1 (lt)
HR (4)	HRP20130677T1 (lt)
HU (2)	HUE031282T2 (lt)
IL (3)	IL218106A0 (lt)
LT (3)	LT2949335T (lt)
ME (2)	ME01536B (lt)
MX (1)	MX2012002082A (lt)
NZ (1)	NZ598661A (lt)
PL (4)	PL3199172T3 (lt)
PT (4)	PT3199172T (lt)
RS (2)	RS55607B1 (lt)
SG (2)	SG10201405806SA (lt)
SI (4)	SI2405749T1 (lt)
SK (1)	SK501352015U1 (lt)
SM (2)	SMT201700057T1 (lt)
TW (3)	TWI643614B (lt)
UA (1)	UA103699C2 (lt)
WO (1)	WO2011022063A1 (lt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2527760T3 (es) *	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US8077333B2 (en) *	2002-09-09	2011-12-13	Canon Kabushiki Kaisha	Printing control apparatus and printing control method
EP2405749B1 (en)	2009-08-20	2013-05-08	Yeda Research and Development Co., Ltd.	Low frequency glatiramer acetate therapy
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) *	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
BR112013008573A2 (pt)	2010-10-11	2016-07-12	Teva Pharma	citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
CN103957705A (zh)	2011-10-10	2014-07-30	泰华制药工业有限公司	适用于预测对醋酸格拉替雷的临床反应的单核苷酸多态性
MX2015004563A (es)	2012-10-10	2015-07-14	Teva Pharma	Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
MX2015008754A (es) *	2013-01-04	2016-04-11	Teva Pharma	Caracterizacion de un medicamento relacionado con acetato de glatiramer.
UY35790A (es)	2013-10-21	2015-05-29	Teva Pharma	Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN103641897B (zh) *	2013-11-27	2017-01-04	深圳翰宇药业股份有限公司	一种合成醋酸格拉替雷的方法
US9763992B2 (en)	2014-02-13	2017-09-19	Father Flanagan's Boys' Home	Treatment of noise induced hearing loss
WO2015195605A1 (en) *	2014-06-17	2015-12-23	Teva Pharmaceutical Industries Ltd.	Transmucosal delivery of glatiramer acetate by oral patches
CN104844697B (zh) *	2014-09-26	2018-10-23	深圳翰宇药业股份有限公司	醋酸格拉替雷的制备方法
US9155775B1 (en) *	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
CN107550853B (zh) *	2016-06-30	2020-06-12	深圳翰宇药业股份有限公司	一种醋酸格拉替雷注射液的制备方法
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
FI3506921T3 (fi)	2016-08-31	2023-07-21	Mapi Pharma Ltd	Glatirameeriasetaattia käsittäviä depot-järjestelmiä
EP4252629A3 (en)	2016-12-07	2023-12-27	Biora Therapeutics, Inc.	Gastrointestinal tract detection methods, devices and systems
MX2019010174A (es)	2017-03-26	2019-10-15	Mapi Pharma Ltd	Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
JP2020525459A (ja)	2017-06-26	2020-08-27	アンスティテュ・パストゥール	Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置
US20200306516A1 (en)	2017-08-14	2020-10-01	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
CA3145269A1 (en)	2019-07-22	2021-01-28	Michel BURCKLEN	Use of ponesimod for the treatment of multiple sclerosis
KR102519053B1 (ko)	2021-02-08	2023-04-06	건국대학교 산학협력단	염산가스의 농도 측정을 위한 수분 전처리 시스템
KR102519054B1 (ko)	2021-03-12	2023-04-06	건국대학교 산학협력단	나피온 드라이어와 수분 전처리장치의 결합시스템
WO2023062511A1 (en) *	2021-10-11	2023-04-20	Actelion Pharmaceuticals Ltd	Methods of treating multiple sclerosis
WO2023061935A1 (en)	2021-10-11	2023-04-20	Actelion Pharmaceuticals Ltd	Methods of treating multiple sclerosis

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL36670A (en)	1971-04-21	1974-09-10	Sela M	Therapeutic basic copolymers of amino acids
ATE55260T1 (de)	1985-10-11	1990-08-15	Duphar Int Res	Automatische spritze.
US5981485A (en)	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
IL113812A (en)	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use
IL119989A0 (en)	1997-01-10	1997-04-15	Yeda Res & Dev	Pharmaceutical compositions for oral treatment of multiple sclerosis
US6214791B1 (en)	1997-01-10	2001-04-10	Yeda Research And Development Co. Ltd.	Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6454746B1 (en)	1997-06-04	2002-09-24	Eli Lilly And Company	Medication delivery apparatus
CA2337688C (en)	1998-07-23	2016-04-05	Yeda Research And Development Co., Ltd.	Treatment of autoimmune conditions with copolymer 1 and related copolymers
EP1105414A2 (en)	1998-07-23	2001-06-13	President And Fellows of Harvard College	Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es)	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
JP4629229B2 (ja)	1998-09-25	2011-02-09	イエダリサーチアンドデベロップメントカンパニーリミテッド	分子量マーカーとして用いるため、また治療用途のための共重合体１関連ポリペプチド
US6800287B2 (en)	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en)	1998-09-25	2003-02-04	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en)	1998-10-02	2000-04-13	Yeda Research And Development Co., Ltd.	Alternate day administration of copolymer 1 for treating autoimmune diseases
WO2000027417A1 (en)	1998-11-12	2000-05-18	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
SI1210115T1 (sl)	1999-08-27	2009-12-31	Genentech Inc	Doziranja za zdravljenje s protitelesi proti ErbB2
ES2243450T3 (es)	2000-01-20	2005-12-01	Yeda Research And Development Co. Ltd.	El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para terapia neuroprotectora.
AU3846901A (en)	2000-02-18	2001-08-27	Yeda Res & Dev	Oral, nasal and pulmonary dosage formualtions of copolymer 1
US7022663B2 (en)	2000-02-18	2006-04-04	Yeda Research And Development Co., Ltd.	Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en)	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL153236A0 (en)	2000-06-05	2003-07-06	Teva Pharma	The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
MXPA02007109A (es)	2000-06-07	2002-12-13	Yeda Res & Dev	El uso del copolimero 1 y peptidos y polipeptidos relacionados y celulas t tratadas con estos para proteger a las celulas del sistema nervioso central de la toxicidad del glutamato.
WO2002076503A1 (en)	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
JP4369234B2 (ja)	2001-12-04	2009-11-18	テバファーマシューティカルインダストリーズリミティド	グラチラマー・アセテートの強度の測定のための方法
WO2004043995A2 (en)	2002-11-13	2004-05-27	Apotex Pharmachem Inc.	Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
CN100464796C (zh)	2002-11-25	2009-03-04	特克法马许可公司	包括可复位安全释放设备的自动注射器
US7274347B2 (en)	2003-06-27	2007-09-25	Texas Instruments Incorporated	Prevention of charge accumulation in micromirror devices through bias inversion
PT1592384E (pt)	2003-01-21	2013-01-28	Yeda Res & Dev	Cop-1 para o tratamento de doenças inflamatórias do intestino
EP1603530A1 (en) *	2003-03-04	2005-12-14	Teva Pharmaceutical Industries Limited	Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
DK1638589T3 (da) *	2003-05-14	2014-06-30	Teva Pharma	Kombinationsterapi med glatirameracetat og mitoxantron til behandling af multipel sklerose
EP1680087A1 (en)	2003-10-31	2006-07-19	Teva Pharmaceutical Industries Limited	Nanoparticles for drug delivery
HUP0303779A2 (en) *	2003-11-20	2006-02-28	Richter Gedeon Vegyeszet	Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
WO2005084377A2 (en)	2004-03-03	2005-09-15	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and riluzole
US7253200B2 (en) *	2004-03-25	2007-08-07	Janssen Pharmaceutica, N.V.	Imidazole compounds
WO2005120542A2 (en)	2004-05-07	2005-12-22	Peptimmune, Inc.	Methods of treating disease with random copolymers
US20060194725A1 (en)	2004-05-07	2006-08-31	James Rasmussen	Methods of treating disease with random copolymers
US7655221B2 (en)	2004-05-07	2010-02-02	Peptimmune, Inc.	Methods of treating disease with random copolymers
US20060229233A1 (en) *	2004-06-25	2006-10-12	Id Biomedical Corporation	Compositions and methods for treating neurological disorders
CA2579038A1 (en) *	2004-09-02	2006-03-16	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
DK1797109T3 (en)	2004-09-09	2016-04-11	Yeda Res & Dev	MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
US7495072B2 (en)	2004-09-09	2009-02-24	Teva Pharmaceutical Industries, Ltd.	Process for preparation of mixtures of polypeptides using purified hydrobromic acid
CA2583589C (en) *	2004-10-29	2012-04-24	Sandoz Ag	Processes for preparing glatiramer
ZA200705874B (en)	2005-02-02	2009-04-29	Teva Pharma	Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en)	2007-10-22	2010-07-01	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
ES2420404T3 (es)	2005-02-17	2013-08-23	Teva Pharmaceutical Industries Ltd.	Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
WO2006116602A2 (en)	2005-04-25	2006-11-02	Yeda Research And Development Company	Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007030573A2 (en)	2005-09-09	2007-03-15	Yeda Research And Development Co. Ltd.	Polypeptides useful for molecular weight determinations
WO2007081975A2 (en) *	2006-01-11	2007-07-19	Teva Pharmaceutical Industries, Ltd.	Method of treating multiple sclerosis
WO2007146331A1 (en)	2006-06-12	2007-12-21	Teva Pharmaceutical Industries, Ltd.	Tannate salt form of polypeptide mixtures, their preparation and use
CN107243099A (zh)	2006-06-30	2017-10-13	艾伯维生物技术有限公司	自动注射装置
DE602007003848D1 (de)	2006-07-05	2010-01-28	Momenta Pharmaceuticals Inc	Verbessertes verfahren zur herstellung von copolymer-1
CA2701172A1 (en) *	2007-10-01	2009-04-09	The Johns Hopkins University	Methods of treating neurological autoimmune disorders with cyclophosphamide
BRPI0819001A2 (pt)	2007-11-28	2014-10-07	Teva Pharma	"método para retardar o acesso de esclerose múltipla clinicamente defenitiva em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão da atividade de doença monitorada por imagem latente de ressonância magnética (mri) em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão dos sintomas de esclerose múltipla definitiva em um paciente, método para reduzir a freqüência de recidiva em um paciente que experimentou um ataque clínico simples sugestivo de esclerose múltipla e que tem pelo menos uma lesão sugestiva de esclerose múltipla, método para retardar a progressão para a esclerose múltipla clinicamente definitiva em um paciente que apresenta um primeiro evento clínico sugestivo de esclerose múltipla e pelo menos uma lesão sugestiva de esclerose múltipla, uso de acetato de glatiramer e acetato de glatiramer
US8920373B2 (en)	2009-07-15	2014-12-30	Teva Pharmaceutical Industries, Ltd.	Reduced volume formulation of glatiramer acetate and methods of administration
ES2383347T3 (es)	2009-07-15	2012-06-20	Teva Pharmaceutical Industries, Ltd.	Formulación de volumen reducido de acetato de glatirámero y procedimientos de administración
EP2405749B1 (en)	2009-08-20	2013-05-08	Yeda Research and Development Co., Ltd.	Low frequency glatiramer acetate therapy
US8759302B2 (en)	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
BR112013008573A2 (pt)	2010-10-11	2016-07-12	Teva Pharma	citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
CN103957705A (zh)	2011-10-10	2014-07-30	泰华制药工业有限公司	适用于预测对醋酸格拉替雷的临床反应的单核苷酸多态性
MX2015004563A (es)	2012-10-10	2015-07-14	Teva Pharma	Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
MX2015008754A (es)	2013-01-04	2016-04-11	Teva Pharma	Caracterizacion de un medicamento relacionado con acetato de glatiramer.
HK1219413A1 (zh)	2013-03-12	2017-04-07	Teva Pharmaceutical Industries Ltd.	利妥昔单抗诱导疗法继而醋酸格拉替雷疗法

2010
- 2010-08-19 EP EP10810282.3A patent/EP2405749B1/en not_active Revoked
- 2010-08-19 SI SI201030270T patent/SI2405749T1/sl unknown
- 2010-08-19 DK DK10810282.3T patent/DK2405749T3/da active
- 2010-08-19 HU HUE15171065A patent/HUE031282T2/hu unknown
- 2010-08-19 EP EP18179172.4A patent/EP3409286B1/en not_active Revoked
- 2010-08-19 PT PT17157735T patent/PT3199172T/pt unknown
- 2010-08-19 EP EP13166080.5A patent/EP2630962B1/en not_active Revoked
- 2010-08-19 DK DK13166080.5T patent/DK2630962T3/en active
- 2010-08-19 EP EP17157735.6A patent/EP3199172B1/en not_active Revoked
- 2010-08-19 DE DE202010018377.4U patent/DE202010018377U1/de not_active Ceased
- 2010-08-19 PL PL17157735T patent/PL3199172T3/pl unknown
- 2010-08-19 LT LTEP15171065.4T patent/LT2949335T/lt unknown
- 2010-08-19 CZ CZ2016-33036U patent/CZ30474U1/cs not_active IP Right Cessation
- 2010-08-19 UA UAA201203259A patent/UA103699C2/ru unknown
- 2010-08-19 KR KR1020147012452A patent/KR20140061559A/ko not_active Ceased
- 2010-08-19 SI SI201031740T patent/SI3199172T1/sl unknown
- 2010-08-19 SI SI201031719T patent/SI2630962T1/sl unknown
- 2010-08-19 ES ES17157735.6T patent/ES2689711T3/es active Active
- 2010-08-19 AT ATGM50231/2015U patent/AT15421U1/de not_active IP Right Cessation
- 2010-08-19 US US12/806,684 patent/US8399413B2/en not_active Expired - Fee Related
- 2010-08-19 CZ CZ2015-31885U patent/CZ29723U1/cs not_active IP Right Cessation
- 2010-08-19 DK DK15171065.4T patent/DK2949335T3/en active
- 2010-08-19 PT PT131660805T patent/PT2630962T/pt unknown
- 2010-08-19 BR BR112012003730-7A patent/BR112012003730A2/pt not_active Application Discontinuation
- 2010-08-19 CN CN2010800369660A patent/CN102625657A/zh active Pending
- 2010-08-19 HR HRP20130677AT patent/HRP20130677T1/hr unknown
- 2010-08-19 SG SG10201405806SA patent/SG10201405806SA/en unknown
- 2010-08-19 PT PT108102823T patent/PT2405749E/pt unknown
- 2010-08-19 SM SM20170057T patent/SMT201700057T1/it unknown
- 2010-08-19 PL PL15171065T patent/PL2949335T3/pl unknown
- 2010-08-19 LT LTEP13166080.5T patent/LT2630962T/lt unknown
- 2010-08-19 KR KR1020127007115A patent/KR20120090044A/ko not_active Ceased
- 2010-08-19 RS RS20170053A patent/RS55607B1/sr unknown
- 2010-08-19 KR KR1020167006001A patent/KR20160038057A/ko not_active Ceased
- 2010-08-19 KR KR1020177031069A patent/KR20170123354A/ko not_active Ceased
- 2010-08-19 EA EA201400394A patent/EA032283B1/ru unknown
- 2010-08-19 JP JP2012525530A patent/JP6038653B2/ja active Active
- 2010-08-19 CN CN201610104429.4A patent/CN105770855A/zh active Pending
- 2010-08-19 SG SG2012011425A patent/SG178495A1/en unknown
- 2010-08-19 NZ NZ598661A patent/NZ598661A/xx unknown
- 2010-08-19 RS RS20130293A patent/RS52885B/sr unknown
- 2010-08-19 EA EA201270292A patent/EA019998B9/ru not_active IP Right Cessation
- 2010-08-19 CN CN201610878988.0A patent/CN107050423A/zh active Pending
- 2010-08-19 ES ES13166080.5T patent/ES2688873T3/es active Active
- 2010-08-19 AU AU2010284666A patent/AU2010284666B2/en not_active Withdrawn - After Issue
- 2010-08-19 PL PL13166080T patent/PL2630962T3/pl unknown
- 2010-08-19 LT LTEP17157735.6T patent/LT3199172T/lt unknown
- 2010-08-19 ES ES10810282T patent/ES2424692T3/es active Active
- 2010-08-19 MX MX2012002082A patent/MX2012002082A/es active IP Right Grant
- 2010-08-19 EP EP15171065.4A patent/EP2949335B1/en not_active Revoked
- 2010-08-19 DK DK17157735.6T patent/DK3199172T3/en active
- 2010-08-19 SI SI201031375A patent/SI2949335T1/sl unknown
- 2010-08-19 PT PT151710654T patent/PT2949335T/pt unknown
- 2010-08-19 HU HUE17157735A patent/HUE039335T2/hu unknown
- 2010-08-19 WO PCT/US2010/002283 patent/WO2011022063A1/en not_active Ceased
- 2010-08-19 ME MEP-2013-81A patent/ME01536B/me unknown
- 2010-08-19 PL PL10810282T patent/PL2405749T3/pl unknown
- 2010-08-19 CA CA2760802A patent/CA2760802C/en active Active
- 2010-08-19 ES ES15171065.4T patent/ES2612001T4/es active Active
- 2010-08-19 ME MEP-2017-17A patent/ME02662B/me unknown
- 2010-08-19 CA CA2876966A patent/CA2876966A1/en not_active Abandoned
- 2010-08-19 EA EA201691347A patent/EA032287B1/ru unknown
- 2010-08-20 TW TW103138861A patent/TWI643614B/zh not_active IP Right Cessation
- 2010-08-20 AR ARP100103062A patent/AR077896A1/es not_active Application Discontinuation
- 2010-08-20 TW TW106100768A patent/TW201733575A/zh unknown
- 2010-08-20 TW TW099128023A patent/TWI477273B/zh active
2011
- 2011-11-30 US US13/308,299 patent/US8232250B2/en not_active Expired - Fee Related
2012
- 2012-02-14 IL IL218106A patent/IL218106A0/en active IP Right Grant
2013
- 2013-02-19 US US13/770,677 patent/US8969302B2/en not_active Expired - Fee Related
- 2013-07-22 CY CY20131100615T patent/CY1114537T1/el unknown
2014
- 2014-02-26 HK HK19100376.3A patent/HK1258008A1/en unknown
- 2014-06-30 IL IL233468A patent/IL233468A0/en unknown
2015
- 2015-01-12 AR ARP150100073A patent/AR099078A2/es not_active Application Discontinuation
- 2015-02-24 US US14/630,326 patent/US20150164977A1/en not_active Abandoned
- 2015-03-30 US US14/673,257 patent/US9402874B2/en active Active
- 2015-05-13 JP JP2015098415A patent/JP6169644B2/ja active Active
- 2015-05-22 US US14/720,556 patent/US9155776B2/en not_active Expired - Fee Related
- 2015-12-18 SK SK50135-2015U patent/SK501352015U1/sk unknown
2016
- 2016-01-06 DK DK201600003U patent/DK201600003Y3/da not_active IP Right Cessation
- 2016-05-06 US US15/148,215 patent/US20160250251A1/en not_active Abandoned
- 2016-12-01 HK HK16113727.5A patent/HK1225310A1/zh unknown
- 2016-12-15 US US15/380,579 patent/US20170095523A1/en not_active Abandoned
2017
- 2017-01-13 HR HRP20170056TT patent/HRP20170056T2/hr unknown
- 2017-01-16 CY CY20171100052T patent/CY1118529T1/el unknown
- 2017-01-25 SM SM201700057T patent/SMT201700057B/it unknown
- 2017-02-22 JP JP2017031335A patent/JP2017132773A/ja not_active Withdrawn
- 2017-03-27 US US15/469,758 patent/US20170196803A1/en not_active Abandoned
- 2017-04-26 IL IL251943A patent/IL251943A0/en unknown
- 2017-07-05 US US15/642,201 patent/US20170296464A1/en not_active Abandoned
- 2017-11-13 US US15/811,495 patent/US20180064639A1/en not_active Abandoned
2018
- 2018-02-28 US US15/908,441 patent/US20180185274A1/en not_active Abandoned
- 2018-06-27 US US16/020,591 patent/US20180311149A1/en not_active Abandoned
- 2018-08-06 HR HRP20181254TT patent/HRP20181254T1/hr unknown
- 2018-08-06 HR HRP20181253TT patent/HRP20181253T1/hr unknown
- 2018-10-19 US US16/165,541 patent/US20190054013A1/en not_active Abandoned
2019
- 2019-02-11 US US16/272,786 patent/US20190175494A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2689711T3 (es)	2018-11-15
TW201521718A (zh)	2015-06-16
NZ598661A (en)	2013-02-22
RS55607B1 (sr)	2017-06-30
SI2949335T1 (sl)	2017-05-31
SMT201700057T1 (it)	2017-03-08
US20110046065A1 (en)	2011-02-24
LT2630962T (lt)	2018-10-25
AU2010284666A1 (en)	2011-09-22
EP2630962A1 (en)	2013-08-28
DK2405749T3 (da)	2013-07-15
EP2405749A4 (en)	2012-08-22
CA2760802C (en)	2016-01-12
US20150164977A1 (en)	2015-06-18
KR20170123354A (ko)	2017-11-07
CZ30474U1 (cs)	2017-03-14
CA2760802F (en)	2011-02-24
UA103699C2 (ru)	2013-11-11
HRP20170056T1 (hr)	2017-03-24
US20190175494A1 (en)	2019-06-13
IL218106A0 (en)	2012-04-30
HK1218250A1 (en)	2017-02-10
IL251943A0 (en)	2017-06-29
US20170196803A1 (en)	2017-07-13
EA032283B1 (ru)	2019-05-31
AU2010284666B2 (en)	2012-12-06
HK1258008A1 (en)	2019-11-01
SI2630962T1 (sl)	2018-10-30
EP2630962B1 (en)	2018-06-27
DK201600003U1 (da)	2016-01-22
US9155776B2 (en)	2015-10-13
KR20140061559A (ko)	2014-05-21
KR20120090044A (ko)	2012-08-16
US8232250B2 (en)	2012-07-31
ME02662B (me)	2017-06-20
TW201119645A (en)	2011-06-16
BR112012003730A2 (pt)	2020-07-21
US20150250845A1 (en)	2015-09-10
CN105770855A (zh)	2016-07-20
HUE031282T2 (hu)	2017-06-28
DK2630962T3 (en)	2018-07-23
HRP20181253T1 (hr)	2018-11-02
JP6169644B2 (ja)	2017-07-26
US8399413B2 (en)	2013-03-19
EP3409286A1 (en)	2018-12-05
ES2612001T3 (es)	2017-05-11
US20130165387A1 (en)	2013-06-27
US8969302B2 (en)	2015-03-03
EP3199172A1 (en)	2017-08-02
HRP20181254T1 (hr)	2019-01-25
US20180311149A1 (en)	2018-11-01
EA201691347A3 (ru)	2016-11-30
EP2405749A1 (en)	2012-01-18
TW201733575A (zh)	2017-10-01
CY1114537T1 (el)	2016-10-05
CZ29723U1 (cs)	2016-08-30
DK3199172T3 (en)	2018-10-08
MX2012002082A (es)	2012-08-23
JP2013502415A (ja)	2013-01-24
US20180185274A1 (en)	2018-07-05
US20170296464A1 (en)	2017-10-19
SI2405749T1 (sl)	2013-10-30
US20150202247A1 (en)	2015-07-23
SMT201700057B (it)	2017-03-08
WO2011022063A1 (en)	2011-02-24
SI3199172T1 (sl)	2018-10-30
SG178495A1 (en)	2012-03-29
US9402874B2 (en)	2016-08-02
HK1165959A1 (en)	2012-10-19
EP2405749B1 (en)	2013-05-08
EA201270292A1 (ru)	2012-12-28
US20190054013A1 (en)	2019-02-21
HRP20130677T1 (en)	2013-10-11
PL2949335T3 (pl)	2017-07-31
EP3199172B1 (en)	2018-07-11
HRP20170056T2 (hr)	2017-12-15
US20170095523A1 (en)	2017-04-06
EA032287B1 (ru)	2019-05-31
IL233468A0 (en)	2014-08-31
ES2612001T4 (es)	2018-02-07
EA019998B9 (ru)	2016-01-29
AT15421U1 (de)	2017-08-15
SK501352015U1 (sk)	2017-07-03
CA2760802A1 (en)	2011-02-24
ME01536B (me)	2014-04-20
DK201600003Y3 (da)	2016-02-12
CA2876966A1 (en)	2011-02-24
CY1118529T1 (el)	2017-07-12
KR20160038057A (ko)	2016-04-06
TWI643614B (zh)	2018-12-11
RS52885B (sr)	2014-02-28
EP3409286B1 (en)	2020-08-12
EA201400394A1 (ru)	2014-10-30
TWI477273B (zh)	2015-03-21
SG10201405806SA (en)	2014-11-27
CN107050423A (zh)	2017-08-18
PT2630962T (pt)	2018-08-01
EA019998B1 (ru)	2014-07-30
ES2424692T3 (es)	2013-10-07
PL3199172T3 (pl)	2019-01-31
AR077896A1 (es)	2011-09-28
PL2405749T3 (pl)	2013-12-31
AR099078A2 (es)	2016-06-29
HK1225310A1 (zh)	2017-09-08
PT3199172T (pt)	2018-10-18
EP2949335B1 (en)	2017-01-04
DE202010018377U1 (de)	2016-02-25
JP6038653B2 (ja)	2016-12-07
EP3199172A8 (en)	2017-10-11
JP2015187125A (ja)	2015-10-29
PL2630962T3 (pl)	2018-12-31
DK2949335T3 (en)	2017-07-31
CN102625657A (zh)	2012-08-01
US20160250251A1 (en)	2016-09-01
ES2688873T3 (es)	2018-11-07
LT2949335T (lt)	2017-03-27
PT2949335T (pt)	2017-02-03
JP2017132773A (ja)	2017-08-03
PT2405749E (pt)	2013-07-22
US20180064639A1 (en)	2018-03-08
HUE039335T2 (hu)	2018-12-28
EP2949335A1 (en)	2015-12-02
US20120071416A1 (en)	2012-03-22
EA201691347A2 (ru)	2016-10-31

Publication	Publication Date	Title
HRP20181254T1 (hr)	2019-01-25	Režim doziranja za multiplu sklerozu
SI2637662T1 (sl)	2019-05-31	Režim odmerjanja za sedacijo s cns 7056 (remimazolam)
IL222055A (en)	2017-08-31	Operational Platform
IL209370A0 (en)	2011-01-31	Dosing regimen
ZA201207298B (en)	2013-06-26	Filling
IL231518A0 (en)	2014-04-30	Ligands for the 1 ep receptor
ZA201303811B (en)	2014-04-30	Triazolopyridine compounds
PL2243721T3 (pl)	2013-06-28	Pojemnik dozujący
IL222277A0 (en)	2012-12-31	Pharmaceutical compositions highly dosed with biotin
AU335331S (en)	2011-03-08	Dispenser
GB2473081B (en)	2012-02-29	Radiator dosing
PL119151U1 (pl)	2011-10-10	Przykrywka-korek do butelki
PT2640340E (pt)	2015-03-02	Dispositivo de dosagem
PL2614004T3 (pl)	2019-04-30	Urządzenie do dozowania produktów
PT2606733T (pt)	2018-11-28	Composição de recheio aerada
AU335332S (en)	2011-03-08	Dispenser
GB201013257D0 (en)	2010-09-22	Carbene transfer agents
GB201002124D0 (en)	2010-03-31	Concept nine
GB0804860D0 (en)	2008-04-16	Dosing fill
GB201100344D0 (en)	2011-02-23	Concept nine
GB201002157D0 (en)	2010-03-31	Packaging thirty-one
GB201017451D0 (en)	2010-12-01	Constructional block
GB201002185D0 (en)	2010-03-31	Packaging nine
PL119280U1 (pl)	2011-02-14	E-nakrętka do butelki
PH32010000342S1 (en)	2011-01-31	Packaging for pens